Control of Tumor Growth by the MMP/Angiostatin Pathway
MMP/血管抑制素途径控制肿瘤生长
基本信息
- 批准号:7162067
- 负责人:
- 金额:$ 31.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-01-10 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:AngiostatinsBiological AssayBiological ModelsCancer ControlCell ProliferationClinical TrialsConflict (Psychology)CutaneousDevelopmentDisseminated Malignant NeoplasmEmployee StrikesEndothelial Cell InhibitorEndothelial CellsEnvironmentEnzymesExtracellular Matrix DegradationGelatinase BGelatinasesGenerationsGenetic ModelsGoalsGrowthHandHumanIn VitroIntegrinsKineticsKnockout MiceLongevityLungLung NeoplasmsMMP9 geneMalignant NeoplasmsMalignant neoplasm of lungMarimastatMatrix Metalloproteinase InhibitorMatrix MetalloproteinasesMetalloproteasesMethodsModelingMolecularMusNeoplasm MetastasisNon-Small-Cell Lung CarcinomaNumbersPancreasPathway interactionsPatientsPlasmaPlasminogenPlayPrimary NeoplasmProcessProphylactic treatmentProtein OverexpressionResearch PersonnelRoleSourceStagingTanomastatTestingTimeTumor AngiogenesisTumor Cell InvasionTumor TissueVascularizationWild Type MouseXenograft Modelangiogenesisantitumor drugcancer cellcancer therapycell growthcell motilitydesignearly onsetimplantationin vivoinhibitor/antagonistlung small cell carcinomamalignant stomach neoplasmpreventprogramsreceptorsizetooltumortumor growthtumor progressiontumorigenic
项目摘要
Angiogenesis is essential for tumor growth and blocking this process is viewed as a valid tool for the
control of cancer growth. We showed that in integrin _l-null mice tumor angiogenesis is reduced compared
to that of wild type mice. This reduction is due to overexpression of matrix metaUoproteinases (MMPs) in
the al-null and consequent generation of angiostatin (an inhibitor of endothelial cell growth) from
plasminogen. Our findings, in contrast to the accepted role of MMPs being pro-tumorigenic, suggest that
excess synthesis of MMPs may play opposite effects on tumor growth. On one hand, increased MMPs may
promote cell migration and metastasis by inducing extracellular matrix degradation. On the other hand,
increased MMPs may prevent tumor growth via angiostatin generation. We showed that inhibition of MMP
expression in vivo leads to decreased synthesis of angiostatin and consequent increased tumor growth and
vascularization. This observation, together with the disappointing results achieved by MMP inhibitors in the
treatment of human cancers, suggests that MMP inhibitors used as anti-tumor drugs might in fact cause a
paradoxical increase in tumor growth and angiogenesis by preventing the generation of inhibitors of
endothelial cell growth. In addition, we also showed that integrin otl is directly involved in the control of
cell proliferation suggesting that this receptor may play a synergistic role together with the MMP/angiostatin
axis by directly regulating endothelial cell proliferation. The role of integrin o_1 and the MMP/angiostatin
axis in tumor progression will be explored in the following aims. 1) Analyze in vivo i) the role of the
MMP/angiostatin axis in the control of primary vs. metastatic human tumors, ii) whether MMP inhibitors can
be successfully used in the prophylaxis of primary vs. metastatic cancers. II) Distinguish between a direct
role of integrin c_l in the control of endothelial cell proliferation and the effect of MMPs or angiostatin by
crossing the otl-null mice with the plasminogen- or MMP-null mice. III) Analyze in real time the effect of
angiostatin and MMP inhibitors on tumor vascularization using the cutaneous window assay.
These studies will help us to determine how stinaulation of the MMP/angiostatin axis can be used as a tool
to inhibit specifically tumor vaseularization and growth.
血管生成对肿瘤生长至关重要,阻断这一过程被认为是治疗肿瘤的有效工具
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMBRA POZZI其他文献
AMBRA POZZI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMBRA POZZI', 18)}}的其他基金
ASMB 2023: Tissue, Matrix, and Pathobiology
ASMB 2023:组织、基质和病理生物学
- 批准号:
10752769 - 财政年份:2023
- 资助金额:
$ 31.86万 - 项目类别:
2023 Fibronectin, Integrins and Related Molecules Gordon Research Conference and Gordon Research Seminar
2023年纤连蛋白、整合素及相关分子戈登研究会议暨戈登研究研讨会
- 批准号:
10608783 - 财政年份:2022
- 资助金额:
$ 31.86万 - 项目类别:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
BLR
- 批准号:
10618237 - 财政年份:2020
- 资助金额:
$ 31.86万 - 项目类别:
BLR&D Merit Review Research Career Scientist (RCS) Award (IK6)
BLR
- 批准号:
10451496 - 财政年份:2020
- 资助金额:
$ 31.86万 - 项目类别:
Integrin/TGF-beta Axis in Tubulointerstitial Fibrosis
肾小管间质纤维化中的整合素/TGF-β轴
- 批准号:
8840580 - 财政年份:2013
- 资助金额:
$ 31.86万 - 项目类别:
Role of Collagen Binding Receptors in Glomerulosclerosis
胶原结合受体在肾小球硬化中的作用
- 批准号:
8803358 - 财政年份:2013
- 资助金额:
$ 31.86万 - 项目类别:
Integrin/TGF-beta Axis in Tubulointerstitial Fibrosis
肾小管间质纤维化中的整合素/TGF-β轴
- 批准号:
8649036 - 财政年份:2013
- 资助金额:
$ 31.86万 - 项目类别:
Role of Collagen Binding Receptors in Glomerulosclerosis
胶原结合受体在肾小球硬化中的作用
- 批准号:
8442087 - 财政年份:2013
- 资助金额:
$ 31.86万 - 项目类别:
Role of Collagen Binding Receptors in Glomerulosclerosis
胶原结合受体在肾小球硬化中的作用
- 批准号:
8971990 - 财政年份:2013
- 资助金额:
$ 31.86万 - 项目类别:
相似海外基金
Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
- 批准号:
520728-2017 - 财政年份:2017
- 资助金额:
$ 31.86万 - 项目类别:
University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10368760 - 财政年份:2017
- 资助金额:
$ 31.86万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10669539 - 财政年份:2017
- 资助金额:
$ 31.86万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9570142 - 财政年份:2017
- 资助金额:
$ 31.86万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9915803 - 财政年份:2017
- 资助金额:
$ 31.86万 - 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
- 批准号:
10259999 - 财政年份:2017
- 资助金额:
$ 31.86万 - 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
- 批准号:
21580130 - 财政年份:2009
- 资助金额:
$ 31.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2005
- 资助金额:
$ 31.86万 - 项目类别:
Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2004
- 资助金额:
$ 31.86万 - 项目类别:
Postdoctoral Fellowships